Tilray Brands (NASDAQ:TLRY) Stock Price Up 6.7% Following Analyst Upgrade

Tilray Brands, Inc. (NASDAQ:TLRY)’s stock price traded up 6.7% during trading on Thursday after Roth Mkm upgraded the stock from a neutral rating to a buy rating. Roth Mkm now has a $10.00 price target on the stock. Tilray Brands traded as high as $6.66 and last traded at $6.55. 5,508,183 shares were traded during mid-day trading, an increase of 49% from the average session volume of 3,697,357 shares. The stock had previously closed at $6.14.

Several other research firms have also issued reports on TLRY. ATB Cormark Capital Markets upgraded shares of Tilray Brands from a “strong sell” rating to a “hold” rating in a research report on Wednesday, December 10th. Wall Street Zen upgraded Tilray Brands from a “sell” rating to a “hold” rating in a research note on Saturday, March 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tilray Brands in a research note on Wednesday, January 21st. Zacks Research raised Tilray Brands from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 11th. Finally, TD Cowen reduced their price objective on Tilray Brands from $10.00 to $7.00 and set a “buy” rating on the stock in a research note on Monday. Three research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $11.20.

Key Headlines Impacting Tilray Brands

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Record Q3 revenue beat and strong international cannabis growth — Tilray reported ~ $207M in Q3 revenue (+11% YoY) with international cannabis up ~73%, driving better-than-expected top-line results. GlobeNewswire press release
• Positive Sentiment: Brokerage support: Jefferies reiterated a Buy and kept a lofty $24 price target, citing improving fundamentals and medium-term visibility — this lifts the bull case on execution and upside if margins improve. Proactive Investors
• Positive Sentiment: Roth MKM upgraded TLRY to Buy with a $10 target — another bullish broker move adding conviction to the upside narrative. BayStreet.CA
• Neutral Sentiment: Company reaffirmed FY26 outlook and provided adjusted EBITDA guidance (FY26 $62–$72M) — guidance maintenance reduces near-term execution risk but still leaves questions on cash flow trajectory. Earnings call transcript
• Neutral Sentiment: Analyst divergence: ATB Cormark trimmed its target to $9 and set sector perform — shows mixed sell-side views (some bullish, some cautious). BayStreet.CA
• Negative Sentiment: EPS missed consensus: TLRY reported a $0.24 loss per share vs. an expected $0.14 loss, which pressured sentiment despite the revenue beat. MarketBeat earnings summary
• Negative Sentiment: Margin pressure and negative cash flow persist — analysts note rising competition and beverage segment weakness; adjusted profitability is improving but net margin remains negative. Seeking Alpha analysis
• Negative Sentiment: Some downgrades and lowered expectations (TD Cowen / other shops) hit consensus sentiment after the print, underlining execution and M&A risks that could cap the stock if momentum stalls. AmericanBankingNews

Institutional Trading of Tilray Brands

A number of hedge funds have recently added to or reduced their stakes in TLRY. Optiver Holding B.V. raised its position in Tilray Brands by 239.4% in the third quarter. Optiver Holding B.V. now owns 224,049 shares of the company’s stock valued at $388,000 after purchasing an additional 158,041 shares during the last quarter. Cresset Asset Management LLC grew its holdings in shares of Tilray Brands by 72.1% during the third quarter. Cresset Asset Management LLC now owns 501,989 shares of the company’s stock worth $868,000 after purchasing an additional 210,267 shares during the last quarter. Tudor Investment Corp ET AL acquired a new position in shares of Tilray Brands in the third quarter valued at approximately $518,000. Caitong International Asset Management Co. Ltd increased its stake in shares of Tilray Brands by 99,204,800.0% in the third quarter. Caitong International Asset Management Co. Ltd now owns 992,049 shares of the company’s stock valued at $1,716,000 after buying an additional 992,048 shares during the period. Finally, Zuckerman Investment Group LLC bought a new position in Tilray Brands in the 3rd quarter valued at approximately $147,000. Institutional investors and hedge funds own 9.35% of the company’s stock.

Tilray Brands Trading Up 6.7%

The business’s fifty day moving average is $7.37 and its 200-day moving average is $10.25. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.72 and a current ratio of 2.81. The firm has a market cap of $763.12 million, a P/E ratio of -0.30 and a beta of 1.96.

Tilray Brands (NASDAQ:TLRY) last posted its earnings results on Wednesday, April 1st. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.10). Tilray Brands had a negative return on equity of 6.35% and a negative net margin of 251.69%.The business had revenue of $206.73 million for the quarter, compared to the consensus estimate of $201.35 million. During the same period in the previous year, the firm earned ($0.87) earnings per share. Analysts predict that Tilray Brands, Inc. will post -0.2 EPS for the current year.

About Tilray Brands

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.